Preclinical Evaluation Confirms Biosimilarity of Breast Cancer Therapy Tuznue to Herceptin
A comprehensive preclinical evaluation demonstrates that the trastuzumab biosimilar Tuznue matches reference Herceptin across critical biofunctional assays and physicochemical quality ...







